Methotrexat Al (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, which is essential for converting folate into its active form. This interruption limits the synthesis of DNA, RNA and proteins in rapidly dividing cells, such as cancer cells and activated immune cells, thereby exerting both antineoplastic and anti‑inflammatory effects.

The exact dose of Methotrexat Al is set by the prescribing clinician based on the specific indication, patient weight, renal and hepatic function, and response to therapy. Dosing regimens can vary widely, so patients should follow the individualized prescription and any monitoring schedule provided by their healthcare professional.

Methotrexate is classified as teratogenic and is contraindicated in pregnancy because it can cause severe fetal malformations. Women of child‑bearing potential should use effective contraception. Limited data exist for breastfeeding, and the drug is generally avoided as it may be excreted in milk and affect the infant.

To request Methotrexat Al, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Methotrexate differs from biologic agents such as TNF‑α inhibitors by acting as a small‑molecule folate antagonist, offering oral or injectable options and a well‑established safety profile. While biologics target specific cytokines, methotrexate provides broader immunomodulation and is often used as first‑line therapy or in combination with newer agents for synergistic effect.

Methotrexat Al should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product in a dry place and avoid exposure to extreme temperatures. No refrigeration is required for this subcutaneous formulation.

Methotrexat Al is given by subcutaneous injection, typically into the abdomen or thigh. The injection should be performed using aseptic technique, with the prescribed volume drawn into a sterile syringe. Patients or caregivers should be trained on proper injection depth, site rotation and disposal of sharps according to local regulations.

The most critical adverse events include severe liver toxicity, profound bone‑marrow suppression leading to infections or bleeding, and pulmonary fibrosis or interstitial pneumonitis. Early detection through regular laboratory monitoring and prompt reporting of respiratory symptoms or signs of infection is essential to mitigate these risks.

Methotrexat Al is contraindicated in patients who are pregnant, have known hypersensitivity to methotrexate, or have severe hepatic or renal impairment. Caution is also advised for individuals with active infections, uncontrolled immunodeficiency, or a history of severe pulmonary disease.